

Cover Story
FreeNews Analysis
By Matthew Bin Han Ong
Now that Joseph R. Biden Jr. is inaugurated and safely ensconced in the White House, cancer groups expect him to pick up where he left off as vice president four years ago—pursuing a sober and ambitious agenda for accelerating progress in cancer research.
In Brief


Funding Opportunities
Clinical Roundup


Drugs & Targets


Trending Stories
- Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched - Blood Cancer United: A new name at the right moment
- With five-year cancer survival at an all-time high, does this mean people are living longer?
- An oncologist navigates terminal sarcoma, insurmountable debt, and “a legacy of grief”
How colleagues and Fargo, ND, neighbors came together to help the Erickson-Abou Zahrs - In The Headlines: Is early detection always good? Inside NCI’s MCD feasibility trial.
- Premarin’s 84-year hold on the market ends as FDA approves a generic version
Trade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer














